Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome

24 Dec 2018

Abstract excerpt

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are diseases of abnormal hematopoietic differentiation with aberrant epigenetic alterations. Azacitidine (AZA) is a DNA methyltransferase inhibitor widely used to treat MDS and AML, yet the impact of AZA on the cell-surface proteome has not been defined. To identify potential therapeutic targets for use in combination with AZA in AML patients, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30584089
DOI: 10.1073/pnas.1813666116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteomePMID 30584089Read ↗

Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodelingSemantic proximity Read ↗

mRNA m5C Alteration in Azacitidine Demethylation Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemiaSemantic proximity Read ↗

Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemiaSemantic proximity Read ↗

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesSemantic proximity Read ↗

Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysisSemantic proximity Read ↗

Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemiaSemantic proximity Read ↗

Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesisSemantic proximity Read ↗

AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivoSemantic proximity Read ↗

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity Read ↗

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewalSemantic proximity Read ↗

Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.